Homology Medicines, Inc.
FIXX
Rank in Stocks
#34157
Homology Medicines, Inc. is a biotechnology firm dedicated to genetic... Homology Medicines, Inc. is a biotechnology firm dedicated to genetic therapeutics, striving to enhance the well-being of patients battling rare inherited disorders. The company leverages its unique platform, which employs adeno-associated virus vectors (AAVHSCs) originating from human hematopoietic stem cells, to introduce genetic treatments directly into the body. This approach facilitates either gene therapy or nuclease-free gene editing solutions for a range of genetic ailments. Crucially, Homology's diverse collection of AAVHSCs enables the precise targeting of multiple disease-affected tissues—such as the liver, central and peripheral nervous systems, bone marrow, heart, skeletal muscles, and eyes—all from a single administration. The leading candidate in their pipeline, HMI-102, is a gene therapy undergoing the Phase 2 pheNIX clinical trial, intended for adult patients with phenylketonuria (PKU). Beyond this, their development portfolio includes HMI-103 for pediatric PKU, HMI-202 targeting metachromatic leukodystrophy, HMI-203 for mucopolysaccharidosis type II, and HMI-104 designed to address paroxysmal nocturnal hemoglobinuria. Established in 2015, Homology Medicines, Inc. maintains its corporate headquarters in Bedford, Massachusetts.
Share Price
$5.14
Last synced: 2026-11-09
Market Cap
$51.40K
Change (1 day)
18.16%
Change (1 year)
449.91%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Homology Medicines, Inc. (FIXX)
Category
Healthcare
Operating Margin for Homology Medicines, Inc. (FIXX)
Operating Margin as of November 2026 TTM: 0.00%
According to Homology Medicines, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2024 the company had an operating margin of 0.00%.
Operating Margin history for Homology Medicines, Inc. from 2016 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2024 | 0.00% | -100.00% |
| 2023 | 725.53% | -223.02% |
| 2022 | -589.76% | 108.81% |
| 2021 | -282.44% | -94.14% |
| 2020 | -4,820.98% | -26.95% |
| 2019 | -6,599.22% | 486.07% |
| 2018 | -1,126.01% | 0.00% |
| 2017 | 0.00% | 0.00% |
| 2016 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Homology Medicines, Inc.'s operating margin
What was Homology Medicines, Inc.'s operating margin in 2024?
In 2024, Homology Medicines, Inc.'s operating margin was 0.00%, compared with 725.53% in 2023.
How has Homology Medicines, Inc.'s operating margin changed since 2019?
From 2019 to 2024, Homology Medicines, Inc.'s operating margin was highest in 2023 (725.53%) and lowest in 2019 (-6,599.22%).
How does Homology Medicines, Inc.'s operating margin compare with similar companies?
Homology Medicines, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.